Long-term results of a multistage treatment for secondary neovascular glaucoma and proliferative diabetic retinopathy with type 2 diabetes mellitus
Open Access
- 27 June 2026
- journal article
- Published by Publishing House Zaslavsky in Archive of Ukrainian Ophthalmology
- Vol. 14 (2) , 125-132
Abstract
Background. Secondary neovascular glaucoma (NVG) is a consequence of severe chronic retinal ischemia that triggers a cascade of angiogenic factors. NVG in patients with proliferative diabetic retinopathy (PDR) and type 2 diabetes is caused by a complex combination of systemic metabolic disorders and local ischemic processes in the retina and other anatomical structures of the eye. The development of modern and safe methods for treating NVG is a pressing task. Objective: to investigate long-term outcomes of a multistage treatment for NVG with PDR and type 2 diabetes. Materials and methods. The study included 68 patients (68 eyes) with PDR, NVG, and type 2 diabetes, divided into two observation groups. Group 1 (35 patients, 35 eyes) underwent staged treatment: stage I — intravitreal injection of an anti-VEGF agent; stage II, performed 5–7 days later — phacoemulsification with monofocal intraocular lens implantation and 25-gauge closed subtotal vitrectomy (CSV) with the stage of panretinal photocoagulation and 18% C3F8 endotamponade; stage III — one month after CSV, transscleral cyclophotocoagulation (CPC) in micropulse mode. Patients in the second group (33 patients, 33 eyes) underwent staged treatment as well: stage I — anti-VEGF therapy; stage II, performed 5–7 days later — phacoemulsification with intraocular lens implantation and 25-gauge CSV with the stage of panretinal photocoagulation and endotamponade using silicone oil (5700 cSt); stage III, performed one month after CSV — CPC in a micropulse mode. Results. One year after completion of stage III, patients showed stabilization of both PDR and NVG. Normalization of intraocular pressure was achieved with topical hypotensive monotherapy in 62.9 % of cases in group 1. In group 2, disease stabilization at one year was also noted, with intraocular pressure normalized in 54.6 % of patients. In 11 indiciduals (33.4 %), silicone oil was not removed due to the high risk of recurrent vitreous hemorrhage, tractional retinal detachment, and progression of the proliferative process. In group 1, PDR progression (25.7 ± 7.4 %), recurrent vitreous hemorrhage and macular edema (22.9 ± 7.1 % each) were most frequently recorded. In group 2, ocular hypertension (45.5 ± 8.7 %), PDR progression (30.3 ± 8.0 %), retinal and preretinal hemorrhages (27.3 ± 7.8 %) were observed most often. No statistically significant differences were found between the groups regarding the incidence of hypertension, indolent uveitis, hyphema, retinal and preretinal hemorrhages, diabetic macular edema and progression of PDR (p > 0.05). Recurrent vitreous hemorrhage was observed only in group 1 — 22.9 ± 7.1 % while it was not recorded in group 2; this difference was statistically significant (p = 0.005). Conclusions. 1. The advanced treatment methods for NVG in patients with PDR and type 2 diabetes proved effective and safe over a one-year follow-up period, achieving intraocular pressure normalization in 62.9 % of group 1 patients and 54.6 % of group 2 patients. 2. Micropulse transscleral CPC, used as the third stage of NVG treatment in PDR, served as an alternative to fistulizing procedures and surgical interventions involving drainage and valve devices, without the drawbacks and complications associated with these methods on long-term follow-up. 3. Additional micropulse CPC, performed when intraocular pressure normalization was not achieved, did not cause complications, adverse effects, or patient dissatisfaction.Keywords
This publication has 29 references indexed in Scilit:
- Surgical Outcomes of Ahmed Glaucoma Valve in Neovascular Glaucoma Secondary to Diabetic Retinopathy Versus Central Retinal Vein OcclusionJournal of Glaucoma, 2025
- Neovascular glaucoma incidence and visual outcomes in treated proliferative diabetic retinopathy with anterior segment neovascularisationEye, 2025
- Medical and surgical management of neovascular glaucomaCurrent Opinion in Ophthalmology, 2025
- Inflammation and patient satisfaction in micropulse versus continuous wave transscleral cyclophotocoagulationBritish Journal of Ophthalmology, 2025
- Early Versus Delayed Vitrectomy for Vitreous Hemorrhage Secondary to Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 2024
- Incidence and risk factor analysis of neovascular glaucoma following vitrectomy in patients with proliferative diabetic retinopathyScientific Reports, 2024
- Effectiveness and Safety of Trabeculectomy Versus Tube Shunt Implantation for Uveitic Glaucoma: A Systematic Review and Meta-AnalysisAmerican Journal of Ophthalmology, 2024
- Analysis aqueous humor lipid profile of neovascular glaucoma secondary to diabetic retinopathy and lipidomic alteration response to anti-VEGF treatmentExperimental Eye Research, 2024
- Sekundäre Offenwinkelglaukome: uveitische Sekundärglaukome, Steroidglaukom, posttraumatische/postoperative Glaukome, tumorbedingte Glaukome und Glaukome im Rahmen eines erhöhten episkleralen VenendrucksDer Ophthalmologe, 2022
- Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical managementSurvey of Ophthalmology, 2020